Besides, MEG3 methylation (HR: 2.14, 95% CI: 1.02‐4.51), low MEG3 expression (HR: 3.01, 95 CI%: 1.54‐5.87), large tumor size (≥ 2 cm) (HR: 1.92, 95 CI%: 1.12‐3.33), advanced TNM grade (HR: 1.79, 95%CI: 1.02‐3.13), and lymphatic metastasis (HR: 1.92, 95CI%: 1.11‐3.23) were likely to indicate poor prognosis of BC patients, after removing impacts exerted by other factors (Table 2). The gene discussed is MEG3; the disease is breast cancer.